These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35258358)

  • 1. Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.
    Zeidi M; Chen KL; Patel J; Desai K; Kim HJ; Chakka S; Lim R; Werth VP
    Lupus; 2022 Apr; 31(4):472-481. PubMed ID: 35258358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.
    Zeidi M; Kim HJ; Werth VP
    J Invest Dermatol; 2019 Feb; 139(2):324-332. PubMed ID: 30227141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidimensional Immune Profiling of Cutaneous Lupus Erythematosus In Vivo Stratified by Patient Response to Antimalarials.
    Patel J; Vazquez T; Chin F; Keyes E; Yan D; Diaz D; Grinnell M; Sharma M; Li Y; Feng R; Sprow G; Dan J; Werth VP
    Arthritis Rheumatol; 2022 Oct; 74(10):1687-1698. PubMed ID: 35583812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus.
    Alves P; Bashir MM; Wysocka M; Zeidi M; Feng R; Werth VP
    J Investig Dermatol Symp Proc; 2017 Oct; 18(2):S57-S63. PubMed ID: 28941496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know.
    Teboul A; Arnaud L; Chasset F
    J Dermatol; 2024 Jul; 51(7):895-903. PubMed ID: 38482997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study.
    Ikeda T; Kanazawa N; Furukawa F
    J Dermatol; 2012 Jun; 39(6):531-5. PubMed ID: 22168306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
    Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
    J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of
    Gardet A; Pellerin A; McCarl CA; Diwanji R; Wang W; Donaldson D; Franchimont N; Werth VP; Rabah D
    Front Immunol; 2019; 10():275. PubMed ID: 30846987
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.
    Yokogawa N; Eto H; Tanikawa A; Ikeda T; Yamamoto K; Takahashi T; Mizukami H; Sato T; Yokota N; Furukawa F
    Arthritis Rheumatol; 2017 Apr; 69(4):791-799. PubMed ID: 27992698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous Toll-like Receptor 9 Pre-Defines Hydroxychloroquine Dosage in Patients with Both Discoid and Subacute Lupus Erythematosus.
    Englert KA; Dyduch G; Kłosowicz A; Spałkowska M; Jaworek AK; Migacz-Gruszka K; Jarosz-Chudek A; Mercuri SR; Szpor J; Mazzoccoli G; Damiani G; Wojas-Pelc A
    Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38004071
    [No Abstract]   [Full Text] [Related]  

  • 12. Expression pattern of tissue-resident memory T cells in cutaneous lupus erythematosus.
    Gu HJ; Song S; Roh JY; Jung Y; Kim HJ
    Lupus; 2021 Aug; 30(9):1427-1437. PubMed ID: 34013817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
    Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
    Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.
    Chasset F; Bouaziz JD; Costedoat-Chalumeau N; Francès C; Arnaud L
    Br J Dermatol; 2017 Jul; 177(1):188-196. PubMed ID: 28112801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
    Chang AY; Piette EW; Foering KP; Tenhave TR; Okawa J; Werth VP
    Arch Dermatol; 2011 Nov; 147(11):1261-7. PubMed ID: 21768444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Mittal L; Zhang L; Feng R; Werth VP
    J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to hydroxychloroquine in Japanese patients with lupus-related skin disease using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N; Tanikawa A; Amagai M; Kato Y; Momose Y; Arai S; Eto H; Ikeda T; Furukawa F
    Mod Rheumatol; 2013 Mar; 23(2):318-22. PubMed ID: 22581095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of smoking in cutaneous lupus erythematosus.
    Piette EW; Foering KP; Chang AY; Okawa J; Ten Have TR; Feng R; Werth VP
    Arch Dermatol; 2012 Mar; 148(3):317-22. PubMed ID: 22105815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus".
    Callen JP
    Arch Dermatol; 2011 Nov; 147(11):1267-8. PubMed ID: 22106112
    [No Abstract]   [Full Text] [Related]  

  • 20. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.
    Piconi S; Parisotto S; Rizzardini G; Passerini S; Terzi R; Argenteri B; Meraviglia P; Capetti A; Biasin M; Trabattoni D; Clerici M
    Blood; 2011 Sep; 118(12):3263-72. PubMed ID: 21576701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.